This inventor holds 1 USPTO granted patent. Top assignee: Medigene Immunotherapies Gmbh. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: **Silke Raffegerst: Innovator in Cancer Immunotherapy**
Introduction
Silke Raffegerst is a distinguished inventor based in Wald, Germany, recognized for her impactful contributions to cancer treatment through innovative immunotherapy solutions. With a strong scientific background and a dedication to advancing medical research, she has made significant strides in the field of T cell receptor (TCR) technology.
Latest Patents
Silke holds a notable patent titled "MAGEA1 specific T cell receptors and their use." This invention pertains to an isolated T cell receptor that is specific for a peptide derived from MAGEA1. It also introduces a polypeptide comprising a functional portion of the TCR. Key components of her invention include a multivalent TCR complex, a nucleic acid that encodes the TCR, and a cell expressing the TCR. Importantly, the patent explores the application of the TCR as a medicament, with particular emphasis on its potential use in cancer treatment.
Career Highlights
Silke Raffegerst is currently associated with Medigene Immunotherapies GmbH, a leading company specializing in the development of innovative immunotherapeutic approaches for cancer treatment. Her role in the company allows her to harness her expertise in TCRs to develop next-generation therapies designed to enhance the body’s immune response against cancerous cells.
Collaborations
While at Medigene Immunotherapies GmbH, Silke collaborates with talented individuals, including her colleagues Carina Wehner and Manon Weis. Together, they contribute to groundbreaking research initiatives aimed at improving patient outcomes through tailored immunotherapeutic solutions.
Conclusion
Silke Raffegerst stands out as a pioneering inventor in the domain of cancer immunotherapy. Her patented work on MAGEA1-specific T cell receptors not only showcases her innovative spirit but also underscores the potential of TCR-based therapies in revolutionizing cancer treatment. With her ongoing contributions, she continues to pave the way for advancements that could significantly impact the future of cancer care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile